Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lopinavir/ritonavir tablets versus soft gel capsules and once-daily versus twice-daily dosing in antiretroviral-naive adults with HIV-1 infection
2005-001430-32Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir, emtricitabine and tenofovir in Human immunodeficiency virus infection type 1 (4 arms), sponsored by Abbott Laboratories. Started Aug 2005; status: completed.
02
Drugs
lopinavir + ritonaviremtricitabinetenofovir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-001430-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001430-32.